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Abstract
Introduction Early, accurate diagnosis is fundamental in the
management of patients with ventilator-associated pneumonia
(VAP). The aim of this qualitative review was to compare various
criteria of diagnosing VAP in the intensive care unit (ICU) with a
special emphasis on the value of clinical diagnosis,
microbiological culture techniques, and biomarkers of host
response.
Methods A MEDLINE search was performed using the keyword
'ventilator associated pneumonia' AND 'diagnosis'. Our search
was limited to human studies published between January 1966
and June 2007. Only studies of at least 25 adult patients were
included. Predefined variables were collected, including year of
publication, study design (prospective/retrospective), number of
patients included, and disease group.
Results Of 572 articles fulfilling the initial search criteria, 159
articles were chosen for detailed review of the full text. A total of
64 articles fulfilled the inclusion criteria and were included in our
review. Clinical criteria, used in combination, may be helpful in
diagnosing VAP, however, the considerable inter-observer
variability and the moderate performance should be taken in
account. Bacteriologic data do not increase the accuracy of
diagnosis as compared to clinical diagnosis. Quantitative
cultures obtained by different methods seem to be rather
equivalent in diagnosing VAP. Blood cultures are relatively
insensitive to diagnose pneumonia. The rapid availability of
cytological data, including inflammatory cells and Gram stains,
may be useful in initial therapeutic decisions in patients with
suspected VAP. C-reactive protein, procalcitonin, and soluble
triggering receptor expressed on myeloid cells are promising
biomarkers in diagnosing VAP.
Conclusion An integrated approach should be followed in
diagnosing and treating patients with VAP, including early
antibiotic therapy and subsequent rectification according to
clinical response and results of bacteriologic cultures.
Introduction
Ventilator-associated pneumonia (VAP) is common in the
intensive care unit (ICU), affecting 8 to 20% of ICU patients
and up to 27% of mechanically ventilated patients [1]. Several
risk factors have been reported to be associated with VAP,
including the duration of mechanical ventilation, and the pres-
ence of chronic pulmonary disease, sepsis, acute respiratory
distress syndrome (ARDS), neurological disease, trauma, prior
use of antibiotics, and red cell transfusions [2]. Mortality rates
in patients with VAP range from 20 to 50% and may reach
more than 70% when the infection is caused by multi-resistant
and invasive pathogens [1-3]. The incidence of VAP-attributa-
ble mortality is difficult to quantify due to the possible con-
founding effect of associated conditions, but VAP is thought
to increase the mortality of the underlying disease by about
30% [3]. VAP is also associated with considerable morbidity,
including prolonged ICU length of stay, prolonged mechanical
ventilation, and increased costs of hospitalization [3,4].
ARDS = Acute respiratory distress syndrome; BAL = Bronchoalveolar lavage; CFU = Colony forming units; CPIS = Clinical pulmonary infection score; 
CRP = C-reactive protein; EF = Elastin fiber; ICU = Intensive care unit; NNIS = National Nosocomial Infection Surveillance; pBAL = Protected bron-
choalvolar lavage; PCT = Procalcitonin; PSB = Protected specimen brush; SIRS = Systemic inflammatory response syndrome; sTREM = Soluble 
triggering receptor expressed on myeloid cells; TBA = Tracheobronchial aspirate; VAP = Ventilator-associated pneumonia.Critical Care    Vol 12 No 2    Rea-Neto et al.
Page 2 of 14
(page number not for citation purposes)
Delayed diagnosis and subsequent delay in initiating appropri-
ate therapy may be associated with worse outcomes in
patients with VAP [1,5,6]; on the other hand, an incorrect diag-
nosis may lead to unnecessary treatment and subsequent
complications related to therapy [1,7,8]. Early, accurate diag-
nosis is, therefore, fundamental in the management of patients
with VAP [9]. Several criteria have been proposed for diagnos-
ing VAP in clinical settings, including clinical manifestations,
imaging techniques, methods to obtain and interpret broncho-
alveolar specimens, and biomarkers of host response. Due to
the lack of an acceptable gold standard, the accuracy of these
methods in diagnosing VAP is controversial.
The aim of this qualitative review was, therefore, to compare
various criteria for diagnosing VAP in the ICU with a special
emphasis on the value of clinical diagnosis, microbiological
culture techniques, and biomarkers of host response.
Materials and methods
We performed a MEDLINE search using the keywords 'venti-
lator associated pneumonia' AND 'diagnosis'. Our search was
limited to human studies published between January 1966
and June 2007. The abstracts of all articles were used to con-
firm our target population (patients with VAP) and the corre-
sponding full-text articles were reviewed for the presence of
data comparing a diagnostic test to a 'gold-standard'. Only
studies of at least 25 adult patients were included. Two inves-
tigators (AR and NC) independently identified the eligible liter-
ature. Predefined variables were collected, including year of
publication, study design (prospective/retrospective), number
of patients included, and disease group. Any inconsistencies
between the two investigators in interpretation of data were
resolved by consensus. To avoid publication bias, abstracts
and full articles were eligible. We also reviewed the bibliogra-
phies of available studies for other potentially eligible studies.
Of 572 articles fulfilling the initial search criteria, 159 articles
were chosen for detailed review of the full text. A total of 64
articles fulfilled the inclusion criteria and were included in our
review.
Results
Accuracy of the clinical diagnosis of VAP
There is no single clinical manifestation that can be used alone
to diagnose VAP. Chest radiology, although very sensitive, is
typically nonspecific [10,11]. Wunderink et al. [12] showed
that no roentgenographic sign correlates well with pneumonia
in mechanically ventilated patients. Lobar or subsegmental
atelectasia, ARDS, alveolar hemorrhage, and/or infarction may
be mistaken for pneumonia [12]. Other clinical signs (fever,
leukocytosis or pulmonary manifestations) have intermediate
predictive values [11,13]. The clinical diagnosis of VAP has,
therefore, traditionally been made by the association of a new
or progressive consolidation on chest radiology plus at least
two of the following variables: fever greater than 38°C, leuko-
cytosis or leukopenia, and purulent secretions. These criteria
were proposed by Johanson et al. [14] (Table 1), and com-
pared to immediate post-mortem lung biopsies by Fàbregas et
al. [11]. The sensitivity was only 69% and specificity not better
than 75% (accuracy of 72%). An increase (or decrease) in the
number of clinical criteria, can increase (or decrease) the spe-
cificity, but at the cost of sensitivity. Despite this relatively low
accuracy, these criteria were recommended by the American
Thoracic Society Consensus Conference on VAP [1].
Combinations of various criteria to establish a diagnosis in
patients with VAP have been suggested and validated (Table
1). The National Nosocomial Infection Surveillance (NNIS)
system was developed in the 1970s by the Centers for Dis-
ease Control as a tool to describe the epidemiology of hospi-
tal-acquired infections and to produce aggregated rates of
infection suitable for inter-hospital comparison, but was never
compared to pathological results. The NNIS system was com-
pared to bronchoalveolar lavage (BAL) fluid cultures in 292
trauma patients and had a sensitivity of 84% and a specificity
of 69% [15]. More recently, the Clinical Pulmonary Infection
Score (CPIS) was proposed by Pugin et al. [16], based on six
variables (fever, leukocytosis, tracheal aspirates, oxygenation,
radiographic infiltrates, and semi-quantitative cultures of tra-
cheal aspirates with Gram stain) [16]. The original description
showed a sensitivity of 93% and specificity of 100%, but this
study included only 28 patients and the CPIS was compared
to quantitative culture of BAL fluid using a 'bacterial index'
defined as the sum of the logarithm of all bacterial species
recovered, which is not considered an acceptable gold stand-
ard for the diagnosis of VAP. Compared to pathological diag-
nosis, CPIS had a moderate performance with a sensitivity
between 72 and 77% and specificity between 42 and 85%
[11,17]. Likewise, CPIS was not sufficiently accurate com-
pared to a BAL fluid-established diagnosis with sensitivity
between 30 and 89% and specificity between 17 and 80%
[17-22] (Table 2). Luyt et al. [19] studied 201 mechanically
ventilated patients in whom strict bronchoscopic criteria were
applied to diagnose or exclude pneumonia. The CPIS
assessed at baseline was calculated retrospectively and did
not differ significantly for patients with or without VAP. The
potential use of CPIS as the sole means to diagnosis VAP was
also evaluated in 158 trauma patients [18]. The average CPIS
was similar between patients with systemic inflammatory
response syndrome (SIRS) (BAL < 105  colony forming
units(CFU)/ml) and those with VAP (BAL > 105 CFUml) with a
sensitivity of 61% and specificity of 43%. In 28 patients with
burn injuries, Pham et al. [23] found that CPIS had a sensitivity
of 30% and specificity of 80% in diagnosing VAP compared
to quantitative BAL fluid culture.
A major limitation of the literature validating CPIS for diagnos-
ing VAP is that BAL culture is not a true gold standard
[11,13,17,24-28]. In addition, the calculation of CPIS was
modified by some authors and different cutoff points were
used to diagnose VAP [19,20]. Importantly, the inter-observerAvailable online http://ccforum.com/content/12/2/R56
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Table 1
Clinical criteria used in diagnosing ventilator-associated pneumonia
Johanson criteria ￿ Presence of a new or progressive radiographic infiltrate
￿ Plus at least two of three clinical features:
- fever > 38°C
- leukocyto sis or leukopeni
- purulent secretions
￿ Temperature ￿ Oxygenation (PaO2/FiO2) ￿ Tracheal secretions (score)
- 0 point: 36.5–38.4 C - 0 point: PaO2/FiO2 > 240 or ARDS -0 point: < 14
- 1 point: 38.5–38.9 - 2 points: PaO2/FiO2 < 240 and no 
evidence of ARDS
-1 point: > 14
- 2 points: < 36 or > 39 -2 points: purulent sputum
Clinical Pulmonary Infection 
Score (CPIS)
￿ Blood leukocytes (cells/μL) ￿ Culture of tracheal aspirate
- 0 point: 4000–11000 -0 point: minimal or no growth
- 1 point: < 4000 or > 11000 -1 point: moderate or more growth
- 2 points: > 500 band forms -2 points: moderate or greater growth
￿ Pulmonary radiography
-0 point: no infiltrate
- 1 point: diffuse or patchy infiltrates
- 2 points: localized infiltrate
Total score of > 6 points suggests ventilator-associated pneumonia
ARDS = acute respiratory distress syndrome
Centers for Disease Control and 
Prevention (CDC)
￿ Radiology signs ￿ Clinical signs
Two or more serial chest radiographs with 
at least 1 of the following:
At least 1 of the following:
- new or progressi ve and persistent 
infiltrate
- fever (temperat ure > 38 C)
- consolidation - leukopeni a (< 4000 WBC) or leukocyto 
sis (> 12000 WBC)
- cavitation - altered mental status, for adults 70 years 
or older, with no other recognized cause
￿ Microbiological criteria
At least one of the following: Plus at least 2 of the following:-
- positive growth in blood culture not related 
to another source of infection
- new onset of purulent sputum, or change 
in character of sputum
- positive growth in culture or pleural field - increased respiratory secretions, or 
increased suctioning requirements
- positive quantitati ve culture from 
bronchoal veolar lavage (> 104) or 
protected specimen brushing (> 103)
- new-onset or worsening cough, or 
dyspnea, or tachypnea
- five percent or more of cells with intracellul 
ar bacteria on direct microsco pic examinati 
on of Gram-stained bronchoal veolar lavage 
fluid
- rales or bronchial sounds
- histopathological evidence of pneumonia - worsening gas exchange
- increased oxygen requirementsCritical Care    Vol 12 No 2    Rea-Neto et al.
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agreement in calculating CPIS was found to be poor (kappa =
0.16) [20].
In summary: Clinical manifestations are usually used in combi-
nation with other features to diagnose VAP. Chest radiography
may be sensitive but is typically nonspecific. NNIS criteria do
not seem to be reliable for VAP diagnosis at the bedside. CPIS
may be a helpful tool in diagnosing VAP, however, the consid-
erable inter-observer variability and the moderate performance
of the CPIS should be taken in account. Further studies are
warranted to validate clinical criteria against pathological
diagnosis.
The role of bacteriological data in improving the 
accuracy of a clinical diagnosis of VAP
Many studies have evaluated the value of bacteriological data
in establishing the diagnosis of VAP compared to pathologi-
cal, clinical, or other bacteriological diagnostic criteria (Tables
2, 3, 4, 5, 6). In a study by Torres et al. [26], quantitative cul-
tures were obtained through BAL (bacterial count = 104 CFU),
protected BAL (pBAL) (104), protected specimen brush
(PSB) (103) and tracheobronchial aspirate (TBA) (105) and
were compared to five different histological and microbiologi-
cal references [26]. Sensitivities for diagnosis of VAP ranged
from 22% to 50% when only histologic reference tests were
used, whereas specificity ranged from 45% to 100%. When
lung histology of guided or blind specimens and microbiology
of lung tissue were combined [11,13,16,24-31], all quantita-
tive diagnostic techniques achieved relatively higher, but still
limited, diagnostic yields (sensitivity range 19% to 87%; spe-
cificity range 31% to 100%). Fabregas et al. [11] also showed
that addition of the results of quantitative cultures to clinical
criteria (Johanson or CPIS) did not increase their accuracy in
diagnosing VAP.
Quantitative cultures obtained by different methods, including
BAL, pBAL, PSB or TBA, seem to be rather equivalent in diag-
nosing VAP [22,31-41,41-58] (Table 4). Compared to a path-
Table 2
Studies comparing clinical criteria to other diagnostic (Dx) tests
First author Sample Dx Tests Gold standard Results
Fabregas, 1999, ** [11] Medical ICU, 25 pts Johanson criteria, CPIS, 
TBA(105), PSB (103), 
pBAL(104), BAL(104)
Pathology + Culture ￿ Johanson criteria (2 items): sens = 69%, spec = 75%.
￿ Any Johanson criteria: Chest Rx: sens = 92%, spec = 
33%; leukocytosis: sens = 77%, spec = 58%; fever: 
sens = 46%, spec = 42%; purulent secretions: sens = 
69%, spec = 42%
￿ CPIS: sens = 77%, spec = 42%.
￿ TBA sens = 69%, spec = 92%.
￿ pBAL sens = 39%, spec = 100%.
￿ BAL sens = 77%, spec = 58%.
￿ PSB sens = 62%, spec = 75%.
￿ QtC added little to clinical diagnostic accuracy
Papazian, 1995, ** [17] Mixed ICU, 38 pts, 
consecutive
BBS (104) & mini-BAL (103) & 
PSB (103) & BAL (104) & 
CPIS
Pathology + Culture ￿ CPIS: sens = 72%; spec = 85%
￿ BBS (104): sens = 83%, spec = 80%
￿ mini-BAL (103): sens = 67%, spec = 80%
￿ BAL: sens (104) = 58%, spec = 95%
￿ PSB: sens (103) = 42%, spec = 95%
￿ BBS was more accurate than PSB
Croce, 2006 *, # [18] Trauma ICU, 158 pts CPIS (>6) BAL (105) ￿ Frequency of VAP: BAL ≥ 105 = 42%, SIRS = 58%
￿ Average CPIS: VAP = 6.9, SIRS = 6.8
￿ CPIS > 6: sens = 61%, spec = 43%
Luyt, 2004 *, ** [19] Mixed ICU, 201 pts CPIS (>6) PSB (103) BAL 
(104)
￿ CPIS: sens = 89%, spec = 44%, k = 0.33, PPV = 
57%, NPV = 84%
Schurink, 2004, ** [20] Mixed ICU, 99 pts CPIS BAL (104) ￿ Frequency of VAP = 69%
￿ ROC curve for CIPS > 6, 7 and 8 = 0.54, 0.64, 0.64; r 
= 0.115
￿ CPIS > 5: sens = 83%, spec = 17%
￿ CIPS >6 or ≤ 6: k 0.16
Fartoukh, 2003, ** [21] Mixed ICU, 68 pts CE & PIS (>6) BAL (104) or PTC 
(103)
￿ CE: sens = 50%, spec = 59%
￿ CPIS > 6: sens = 60%, spec = 59%
￿ Adding positive Gram stain to CIPS improves 
diagnostic accuracy
Miller, 2006, ** [15] Trauma ICU, 292 pts NNIS BAL (105) ￿ k = 0.73.
￿ Sens = 84%, spec = 69%, PPV = 83%, NPV = 70%
Pham, 2007*, ** [23] Mixed ICU, 28 burn pts CPIS BAL ￿ CPIS: sens = 30%, spec = 80%, PPV = 70%, NPV = 
50%
Pugin, 1991, **, [16] Surgical ICU, 28 pts, CPIS & mini-BAL (BI ≥ 5) BAL (BI ≥ 5) ￿ CPIS: sens = 93%, spec = 100%, r = 84% (CIPS and 
mini-BAL), r = 76% (CPIS and BAL)
￿ Mini-BAL: sens = 73%, spec = 96%
CPIS = clinical pulmonary infection score; TBA = tracheobronchial aspirate; PSB = protected specimen brush; pBAL = protected BAL or 'mini-BAL'; BAL = 
bronchoalveolar lavage; sens = sensitivity; spec = specificity; QtC = quantitative culture; BBS = blind bronchial sampling; SIRS = systemic inflammatory response 
syndrome; PPV = positive predictive value; NPV = negative predictive value; CE = clinical estimate; NNIS = National nosocomial infection surveillance system; BI = 
bacterial index; ICU = intensive care unit; *retrospective; **consecutive; #convenient.Available online http://ccforum.com/content/12/2/R56
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ologically confirmed diagnosis of VAP, BAL (104) had a
sensitivity between 19 and 83% and specificity between 45
and 100%, PSB (103) a sensitivity between 36 and 83% and
specificity between 50 and 95%, pBAL (104) a sensitivity
between 39 and 80% and specificity of 66 to100%, and TBA
(105) a sensitivity between 44 to 87% and specificity between
31 to 92% (Table 3) [10,11,13,17,24-30]. Torres et al. [26]
demonstrated that prior antibiotic use considerably decreased
the sensitivity of the cultures of BAL samples. Kirtland et al.
[27] and Rouby et al. [30] reported that the microorganism
Table 3
Studies comparing quantitative cultures with pathology
First author Sample Dx Tests Gold standard Results
Balthazar, 2001, ** [13] Mixed ICU, 37 pts BAL (104) & Gram & cells from 
BAL
Pathology + Culture ￿ BAL: sens = 19%, spec = 94%; fever: sens = 50%, spec 
= 76%; leucocytosis (>10000): sens = 60%, spec = 
76%; Gram stain: sens = 85%, spec = 94%; total cell 
(>400000): sens = 90%, spec = 94%.
Torres, 2000, ** [26] Medical ICU, 25 pts TBA (105) & PSB (103) & BAL 
(104) & pBAL (104)
Pathology + Culture ￿ TBA: sens = 50%, spec = 67%.
￿ PSB: sens = 67%, spec = 75%.
￿ pBAL: sens = 63%, spec = 83%.
￿ BAL: sens = 83%, spec = 68%.
Fabregas, 1999, ** [11] MIxed ICU, 25 pts Johanson & CPIS & TBA (105), 
PSB (103), pBAL (104) and 
BAL (104)
Pathology + Culture ￿ Johanson criteria (2): sens = 69%, spec = 75%.
￿ Any Johanson criteria: Chest Rx: sens = 92%, spec = 
33%; leukocytosis: sens = 77%, spec = 58%; fever: sens 
= 46%, spec = 42%; purulent secretions: sens = 69%, 
spec = 42%.
￿ CPIS: sens = 77%, spec = 42%.
￿ TBA: sens = 69%, spec = 92%.
￿ pBAL: sens = 39%, spec = 100%.
￿ BAL: sens = 77%, spec = 58%.
￿ PSB: sens = 62%, spec = 75%.
￿ QtC increased little to clinical diagnosis accuracy.
Papazian, 1997, # [29] Mixed ICU, 28 pts Gram & ICO Pathology + Culture ￿ BBS Gram stain: sens = 56%, spec = 73%.
￿ mini-BAL Gram Stain: sens = 44%, spec = 87%.
￿ BAL Gram stain: sens = 56%, spec = 100%.
￿ BBS ICO (>10%): sens = 56%, spec = 40%.
￿ Mini-BAL ICO (>5%): sens = 67%, spec = 53%.
￿ BAL ICO (>4%): sens = 56%, spec = 40%.
Kirtland, 1997, ** [27] Mixed ICU, 39 pts TA &PSB & pPSB & BAL & 
BAL cells
Pathology + Culture ￿ TA: sens = 87%, spec = 31%.
￿ pPSB: sens = 30%, spec = 81%.
￿ PSB: sens = 44%, spec = 81%.
￿ BAL: sens = 65%, spec = 63%.
￿ >50% neutrophils in BAL: sens = 100%.
Marquette, 1995, ** [28] Mixed ICU, 28 pts TA (105 & 106) & PSB (103) & 
BAL (104)
Pathology ￿ TA (105): sens = 63%, spec = 75%.
￿ TA (106): sens = 50%, spec = 85%.
￿ PSB (103): sens = 57%, spec = 88%.
￿ BAL (104): sens = 47%, spec = 100%.
￿ ICO (any%): sens = 36%, spec = 100%.
Torres, 1996 *, ** [25] Mixed ICU, 25 pts ICO (≥ 5%), mini-BAL (104) & 
BAL (104)
Pathology ￿ ICO (≥ 5%) compared to mini-BAL: PPV = 75%, NPV = 
83%.
￿ ICO (≥ 5%) compared to BAL: PPV = 57%, NPV = 8 
3%.
￿ Mini-BAL: sens = 22%, spec = 100%.
￿ BAL: sens = 45%, spec = 55%.
Papazian, 1995, ** [17] MIxed ICU, 38 pts BBS (104) & mini-BAL (103) & 
PSB (103) & BAL (104) & 
CPIS
Pathology + Culture ￿ CPIS: sens = 72%, spec = 85%.
￿ BBS (104): sens = 83%, spec = 80%.
￿ mini-BAL (103): sens = 67%, spec = 80%.
￿ BAL (104): sens = 58%, spec = 95%.
￿ PSB (103): sens = 42%, spec = 95%.
Torres, 1994, ** [24] Mixed ICU, 30 pts TBA (105) & PSB (103) & BAL 
(104) & Clinical data
Pathology ￿ Clinical data: fever: sens = 55%, spec = 58%; purulent 
secretions: sens = 83%, spec = 33%; Rx infiltrate: sens = 
78%, spec = 42%.
￿ Pulmonary biopsy culture (≥103): sens = 40%, spec = 
45%.
￿ Quantitative cultures: TBA: sens = 44%, spec = 48%; 
PSB: sens = 36%, spec = 50%; BAL: sens = 50%, spec 
= 45%.
Rouby, 1989, ** [30] Surgical ICU, 59 
pts
pBAL Pathology + culture ￿ pBAL: sens = 80%, spec = 66% to identify VAP; sens = 
73% to identify the microorganism.
Chastre, 1984, ** [10] Mixed ICU, 26 pts PSB (103) Lung culture ￿ PSB correlated well to lung cultures, especially in the 
subgroup of patients who received no antibiotics during 
the week preceding their death.
ICU = intensive care unit; BAL = bronchoalveolar lavage; sens = sensitivity; spec = specificity; TBA = tracheobronchial aspirate; PSB = protected specimen brush; 
pBAL = protected BAL or 'mini-BAL'; CPIS = clinical pulmonary infection score; QtC = quantitative culture; ICO = intracellular organism; BBS = blind bronchial 
sampling; TA = tracheal aspiration; PPV = positive predictive value; NPV = negative predictive value; * = retrospective; ** = consecutive; # convenientCritical Care    Vol 12 No 2    Rea-Neto et al.
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Table 4
Studies comparing quantitative cultures using various techniques or cutoff points
First author Sample Dx tests Gold standard Results
Mondi, 2005, # [31] Trauma ICU, 39 pts TA (104) & (105)B A L  ( 1 0 5)￿  T A  ( 1 0 4): sens = 95%, spec = 58%, k = 0.5339 (p < 
0.0001).
￿ TA (105): sens = 90%, spec = 68%, k = 0.6384 (p < 
0.0001).
Brun-Buisson, 2005, ** 
[32]
Mixed ICU, 68 pts TA (score ≥4+) & bPTC 
(103) & PTC (103)
BAL (104 or ICO > 
2%)
￿ TA: sens = 77%, spec = 81%.
￿ bPTC: sens = 77%, spec = 97%.
￿ PTC: sens = 77%, spec = 94%.
Davis, 2005, # [42] Trauma ICU, 155 pts Gram (BAL) CDC + BAL (105) ￿ Gram (BAL): sens = 88% (any organism).
￿ Gram (BAL): sens = 73%, spec = 49%; PPV = 78%, 
NPV = 42%, accuracy = 65% (Gram-negative).
￿ Gram (BAL): sens = 87%, spec = 59%; PPV = 68%, 
NPV = 83%, accuracy = 74% (Gram-positive).
Croce, 2004, ** [43] Trauma ICU, 526 pts BAL (104 & 105)B A L  ( 1 0 5) and ClEvol ￿ BAL (105): sens = 95%, spec = 10%.
￿ BAL (104): sens = 99%, spec = 70%.
Miller, 2003, ** [44] Trauma ICU, 168 pts BAL (102 to 104)B A L  ( 1 0 5) ￿ BAL (104 and 103): increased sensitivity = 14%.
￿ BAL (102): increased sensitivity = 16%.
Sirvent, 2003, ** [45] Mixed ICU, 82 pts ICO Mini-BAL (103)￿  I C O  ≥ 2%: sens = 80%, spec = 82%.
￿ ICO ≥ 2% better than 1, 5, 7 and 10%.
Wu, 2002, ** [35] Medical ICU, 48 pts TA (105)P S B  ( 1 0 3) or BAL 
(104)
￿ TA and PSB: sens = 91%, spec = 72%; PPV = 75%, 
NPV = 90%.
￿ TA and BAL: sens = 91%, spec = 75%; PPV = 78%, 
NPV = 90%.
Duflo, 2001, ** [46] Mixed ICU, 104 pts Gram stain (mini-BAL) Mini-BAL (103) ￿ Gram stain: sens = 76%, spec = 100%, k = 0.73, 
concordance = 86%.
Prekates, 1998,*, ** [47] BAL ￿ Gram stain: sens = 77%, spec = 87%, PPV = 71%, 
NPV = 90%.
Bello, 1996, *, ** [48] ICU, 74 pts, consecutive Mini-PSB PSB and BAL ￿ BAL and PSB: concordance = 92%.
￿ mini-PSB and BAL: concordance = 84%.
￿ mini-PSB and PSB: concordance = 85%.
Pugin, 1991, ** [16] Surgical ICU, 28 pts, CPIS & mini-BAL (BI ≥ 
5)
BAL (BI ≥ 5) ￿ CPIS: sens = 93%, spec = 100%, r = 84% (CIPS and 
mini-BAL), r = 76% (CPIS and BAL).
￿ Mini-BAL: sens = 73%, spec = 96%.
Jourdain, 1995, ** [36] Mixed ICU, 39 pts TA (103 to 107)P S B  ( 1 0 3) and ICO (≥ 
5%)
￿ TA (103): sens = 90%, spec = 26%, accuracy = 47%.
￿ TA (104): sens = 84%, spec = 40, accuracy = 54%.
￿ TA (105): sens = 79%, spec = 66%, accuracy = 70%.
￿ TA (106): sens = 68%, spec = 84%, accuracy = 79%, 
correlation = 40% (TA and PSB).
￿ TA (107): sens = 21%, spec = 92%, accuracy = 68%.
Marik, 1995, ** [37] Medical ICU, 53 pts Mini-PSB (103)P S B  ( 1 0 3) ￿ Mini-PSB and PSB: quantitative agreement = 85%.
Kollef, 1995, # [38] Medical ICU, 42 pts Mini-BAL (103) & PSB 
(103)
Johanson (ATS) ￿ Mini-BAL: sens = 100%, spec = 95%.
￿ PSB: sens = 71%, spec = 100%. Good agreement 
between mini-BAL and PSB cultures: k = 0,63, 
concordance = 83%.
Rumbak, 1994, # [39] Mixed ICU, 38 pts TA PSB (103) ￿ TA: sens = 97%, spec = 50%, PPV = 91%, NPV = 
80%.
Valles, 1994, ** [49] Mixed ICU, 42 pts ICO & BAL Clinical criteria + PSB 
(103)
￿ BAL (103): sens = 89%, spec = 79%, PPV = 76%, 
NPV = 90%.
￿ BAL (104): sens = 89%, spec = 100%, PPV = 100%, 
NPV = 92%.
￿ ICO (≥ 2%): = 78%, spec = 88%, PPV = 82%, NPV = 
84%.
￿ ICO (≥ 5%): = 67%, spec = 96%, PPV = 92%, NPV = 
79%.
￿ ICO (≥ 7%): = 67%, spec = 100%, PPV = 100, NPV 
= 80%.
￿ ICO for Pseudomonas: lower sens.
￿ Previous antibiotic treatment decreased sens.
El-Ebiary, 1993, ** [40] Medical ICU, 102 pts TA, PSB and BAL Clinical ad hoc ￿ TA (105): sens = 70%, spec = 72%, accuracy = 71%.
￿ PSB (103): sens = 60%, spec = 93, accuracy = 64%.
￿ BAL (104): sens = 57%, spec = 87%, accuracy = 
67%.
Elatrous, 2004, ** [33] Medical ICU, 100 pts, TA (102 to 106)P T C  ( 1 0 6)￿  T A  ( 1 0 2): sens = 96%, spec = 66%.
￿ TA (103): sens = 94%, spec = 66%.
￿ TA (104): sens = 92%, spec = 85%, k = 0,78.
￿ TA (105): sens = 84%, spec = 90%.
￿ TA (106): sens = 44%, spec = 94%.Available online http://ccforum.com/content/12/2/R56
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identified in quantitative culture from a transtracheal method
frequently does not correlate well with the culture obtained
from pathological samples. In addition, several studies [59-61]
have challenged the reliability of quantitative cultures. Timsit et
al. [56] reported moderate intra-individual variability in compar-
ing two consecutive PSB procedures performed in the same
lung. Likewise, Gerbeaux et al. [57] performed two BAL pro-
cedures in the same lung area to distinguish between the
presence and absence of bacterial pneumonia and showed a
repeatability of only 75%. Butler et al. [58] compared the
results of blind PSB sampling from the contralateral lung and
PSB from the site of the observed infiltrates; the concordance
rate between the two samples was only 53%.
Mimoz, 2000, ** [50] Mixed ICU, 134 pts, Gram stain (10 and 50 
fields)
PSB (103) or bPTC 
(103)
￿ Gram (10 fields) vs PSB: sens = 74%, spec = 94%.
￿ Gram (10 fields) vs PTC: sens = 81%, spec = 100%.
￿ PSB: correlation between morphology and culture: 
sens = 54%, spec = 86%.
￿ bPTC: correlation between morphology and culture: 
sens = 69% and spec = 89%.
Flanagan, 2000, ** [22] Mixed ICU, 145 pts, Mini-BAL (104) & BAL 
(104) & PSB (103) & 
CPIS & BI (≥5)
Clinical (modified 
CDC)
￿ Mini-BAL: sens = 74%, spec = 70%, PPV = 17%, 
NPV = 96%.
￿ BAL: sens = 76%, spec = 71%, PPV = 35%, NPV = 
93%.
￿ PSB: sens = 68%, spec = 86%, PPV = 54%, NPV = 
95%.
￿ CPIS > 7: sens = 85%, spec = 91%, PPV = 61%, 
NPV = 96%.
￿ BI: sens = 62%, spec = 53%.
Allaouchiche, 1999, ** 
[51]
Mixed ICU, 118 pts, ICO (≥ 2%) & Gram 
stain (BAL)
PSB (103) ￿ ICO: sens = 86%, spec = 78%, PPV = 68%, 
NPV = 91%, k = 0.616, concordance = 81.5%.
￿ Gram stain: sens = 90%, spec = 73%, PPV = 
64%, NPV = 91%, k = 0.58, concordance = 
79.4%.
￿ Correlation between morphology and culture: 
complete = 51%, partial = 39.2%, no correlation 
= 9.8%.
Casetta, 1999, ** [53] Mixed ICU (Cancer), 
42 pts
PTC (103)P S B  ( 1 0 3) ￿ PTC: sens = 67%, spec = 93%; PPV = 71%, 
NPV = 91%, agreement = 87%.
Souweine, 1998, ** 
[54]
Mixed ICU, 52 pts Antibiotic use & ICO 
(≥ 5%), PSB (103) & 
BAL (105)
Clin ad hoc ￿ ICO: sens = 71% (no antibiotics), 50% (current 
antibiotics), 67% (recent antibiotics).
￿ PSB: sens = 88% (no antibiotics), 77% 
(current antibiotics), 40% (recent antibiotics).
￿ BAL: sens = 71% (no antibiotics), 83% (current 
antibiotics), 38% (recent antibiotics).
Allaouchiche, 1996, ** 
[52]
Mixed ICU, 132 pts ICO PSB (103) + clinical 
evolution
￿ ICO (≥ 2%): sens = 84%, spec = 80%, PPV = 
69%, NPV = 90%, ROC = 0.888.
Barreiro, 1996, ** [55] Mixed ICU, 93 pts pBAL (104) & Gram 
stain & ICO (≥ 2%)
PSB (103) + 
Follow-up
￿ pBAL: sens = 87%, spec = 91%, PPV = 87%, 
NPV = 91%.
￿ ICO: sens = 75%, spec = 98%, PPV = 96%, 
NPV = 86%.
Torres, 1989, ** [41] Mixed ICU, 34 pts BAL & BI PTC & BI ￿ BAL: spec = 71%, r = 0,72 (between BAL and 
BI)
￿ PTC: spec = 86%, r = 0.78 (between PTC and 
BI)
Timsit, 1993, ** [56] Mixed ICU, 26 pts PSB 1 PSB 2 (2 minutes 
interval)
￿ PSB 1: sens = 67%, spec = 94%.
￿ PSB 2: sens = 54%, spec = 94%.
Gerbeaux, 1998, ** 
[57]
Mixed ICU, 44 pts BAL 1 BAL 2 (30 minutes 
interval)
￿ BAL 1-BAL2 repeatability = 75% with no bias, 
agreement = 47%.
Butler, 2004, ** [58] Surgical ICU, 34 pts Blind PSB Directed PSB ￿ Blind PSB and Directed PSB: concordance = 
53%.
Wood, 2003, ** [34] Trauma ICU, 90 pts TA & BDPB & BPB & 
BAL
BDPB & BAL ￿ TA & BAL: k = 0.535.
￿ BPB & BDPB: k = 0.467.
￿ BPB & BAL: k = 0.547.
ICU = intensive care unit; TA = tracheal aspiration; BAL = bronchoalveolar lavage; sens = sensitivity; spec = specificity; bPTC = blinded 
protected telescoping catheter; PTC = protected (plugged) telescoping catheter; ICO = intracellular organism; CDC = center for disease control; 
PPV = positive predictive value; NPV = negative predictive value; ClEvol: clinical evolution; PSB = protected specimen brush; CPIS = clinical 
pulmonary infection score; BI = bacterial index; ATS = American Toracic Society; vs = versus; BDPB = bronchoscope-directed protected 
brushings; BPB = blind protected brushing via endotracheal tube; *retrospective; **consecutive; #convenient.
Table 4 (Continued)
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The rate of positive blood cultures in VAP ranges from 8 to
20% [62,63]. In 162 patients with suspected VAP, Luna et al.
[64] showed that the sensitivity of blood cultures in 90
patients with VAP confirmed by BAL was only 26% and, in
many cases, the bacteria isolated in the blood cultures
probably had an extrapulmonary source. Blood cultures were
also positive in 5 of 72 patients without VAP (6.9%).
Since bacteriological cultures require some days for the
results to be available at the bedside, several studies have
investigated the value of cytological characteristics of the
available bronchoalveolar specimens in diagnosing VAP.
These characteristics include the number of inflammatory cells
and Gram stains. The rapid availability of cytological data has
been shown to be useful in initial therapeutic decisions in
patients with suspected VAP [42,46,47,50,51,65-67]. The
presence of more than 2% inflammatory cells had a sensitivity
of 75% to 86% and a specificity of 78% to 98% in diagnosing
the first episode of VAP (Table 6). Other studies
[46,49,50,68] investigated other cutoff values and reported
contradictory results. Prior antibiotic use was also shown to
influence the number of inflammatory cells in patients with VAP
[45,54]. Infections with Pseudomonas aeruginosa were also
shown to decrease the sensitivity of cytological data in diag-
nosing VAP compared with other bacteria [49]. The presence
of bacteria in Gram stains of bronchoalveolar specimens had
a sensitivity of 44% to 90% and specificity of 49% to 100% in
identifying patients with VAP (Table 6). Davis et al. [42]
showed that the accuracy of Gram stains was slightly better
for Gram-positive than for Gram-negative microorganisms.
Although the presence of bacteria on Gram stain appears to
have a reasonable accuracy compared to quantitative culture
available two to three days later, the agreement between the
two methods ranges from 79.4 to 86% (Table 6).
In summary: Bacteriologic data do not increase the accuracy
of diagnosis when compared to clinical diagnosis. Quantita-
tive cultures obtained by different methods, including BAL,
pBAL, PSB or TBA seem to be fairly equivalent in diagnosing
VAP. Blood cultures are relatively insensitive to diagnose
pneumonia. The rapid availability of cytological data, including
inflammatory cells and Gram stains, may be useful in initial
therapeutic decisions in patients with suspected VAP but may
be influenced by prior antibiotic use and the infecting
microorganism.
Biomarkers and VAP diagnosis
Many biological markers have been studied in an effort to
improve the rapidity and performance of current diagnostic
procedures in VAP. When the anatomical and mechanical
defense mechanisms that prevent microorganisms from reach-
ing alveoli are overwhelmed, a complex host response devel-
ops [1]. Microbial products activate alveolar macrophages,
which release multiple endogenous mediators locally. Among
these mediators, tumor necrosis factor alpha, interleukin-1β,
and other cytokines are increased in various types of pulmo-
nary infections and thus have potential prognostic implica-
tions. However, there is no cutoff value for such mediators that
could be used to diagnose pneumonia. Several biomarkers
have been investigated for diagnosing VAP (Table 7). The
presence of elastin fiber (EF), a marker of parenchymal lung
destruction, in tracheal secretion has been proposed to differ-
Table 5
Studies comparing quantitative cultures to clinical diagnosis
First author Sample Dx tests Gold standard Results
Camargo, 2004, ** [59] Mixed ICU, 106 pts TA (105 and 106) & TA 
(qualit)
Clinical (ad hoc) ￿ TA (106): sens = 26%, spec = 78%, PPV = 20%, NPV 
= 83%
￿ TA (105): sens = 65%, spec = 48%, PPV = 21%, NPV 
= 87%
￿ TA (qualit): sens = 81%, spec = 23%, PPV = 18%, 
NPV = 86%
Mentec, 2004, ** [60] Mixed ICU, 63 pts TA (105), bPTC (103), PTC 
(103), BAL (104)
Clinical + Rx (ad hoc) ￿ For quantitative cultures: TA: sens = 82%, spec = 
67%, ROC = 0,78; bPTC: sens = 62%, spec = 94%, 
ROC = 0,83; PTC: sens = 71%, spec = 94%, ROC = 
0,85; BAL: sens = 94%, spec = 100%, ROC = 0.98
￿ For Gram stain: TA: sens = 94%, spec = 50%; bPTC: 
sens = 56%, spec = 94%; PTC sens = 65%, spec = 
83%; BAL sens = 100%, spec = 94%
Woske, 2001, ** [61] Surgical ICU, 103 pts, 
consecutive
BAL (104) & PSB (103) & 
TA (105 and 106)
CPIS ≥6 ￿ BAL: sens = 90%.
￿ PSB: sens = 83%.
￿ TA (105): sens = 90%.
￿ TA (106): sens = 50%.
Meduri, 1992, ** [84] Mixed ICU, 25 pts pBAL (104) & PSB Clinical ￿ pBAL: Spec = 100%, NPV = 100%
Salata, 1987, ** [85] Mixed ICU, 51 pts TA Clinical ￿ TA: higher Gram stain grading for neutrophils: p < 0.05
￿ TA: higher bacterial colony count: p < 0.05
Castro, 1991, ** [86] Mixed ICU, 103 pts PSB (103) Clinical ￿ PSB: sens = 84%, spec = 67%
ICU = intensive care unit; TA = tracheal aspiration; qualit. = qualitative; BAL = bronchoalveolar lavage; sens = sensitivity; spec = specificity; bPTC = blinded protected 
telescoping catheter; PTC = protected (plugged) telescoping catheter; PPV = positive predictive value; NPV = negative predictive value; PSB = protected specimen 
brush; CPIS = clinical pulmonary infection score; pBAL = protected bronchoalveolar lavage; **consecutiveAvailable online http://ccforum.com/content/12/2/R56
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entiate colonization from infection of the lung. However, the
presence of EF in tracheal aspirates had low sensitivity (32%)
and only reasonable specificity (72%) in diagnosing VAP [69].
In 22 patients with ARDS, Shepherd et al. [70] found that EF
had a sensitivity of only 40% in diagnosing VAP. This may be
due to the fact that EF correlates with lung destruction, more
than infection per se.
Procalcitonin (PCT) and C-reactive protein (CRP) measure-
ments have been shown to improve the clinical accuracy in
identifying patients with SIRS caused by infection from SIRS
of other causes. Serum PCT levels had a better performance
than alveolar PCT concentrations, with a sensitivity of 41%
and a specificity of 100% [71]. In patients after cardiac arrest
and return of spontaneous circulation, PCT had a sensitivity of
100% and a specificity of 75% for the diagnosis of VAP [72].
Póvoa et al. showed that CRP (>9.6 mg/dl) had a good accu-
racy for VAP, with sensitivity of 87% and a specificity of 88%
in a population of general ICU patients [73]. In addition, in 47
patients with microbiologically confirmed VAP, high CRP lev-
els were associated with poor outcome [74].
The detection of soluble triggering receptor expressed on
myeloid cells (sTREM)-1 in BAL fluid may be useful in estab-
lishing or excluding a diagnosis of bacterial or fungal pneumo-
nia. Gibot et al. [75] studied 148 patients with suspected
pneumonia and measured sTREM-1 in their BAL fluid. These
authors showed that the presence of sTREM by itself was
more accurate than any clinical findings or laboratory values in
identifying the presence of bacterial or fungal pneumonia.
Questions about the lack of a gold standard definition for VAP
may have hampered classification of some of patients. In 28
Table 6
Studies comparing cytological examination to quantitative cultures
First author Sample Dx tests Gold standard Results
Davis, 2005, # [42] Trauma ICU, 155 pts Gram (BAL) CDC + BAL (105) ￿ Gram (BAL): sens = 88% (any organism).
￿ Gram (BAL): sens = 73%, spec = 49%, PPV = 78%, NPV 
= 42%, accuracy = 65% (Gram-negative).
￿ Gram (BAL): sens = 87%, spec = 59%, PPV = 68%, NPV 
= 83%, accuracy = 74% (Gram-positive).
Sirvent, 2003, ** [45] Mixed ICU, 82 pts ICO Mini-BAL (103)￿  I C O  ≥ 2%: sens = 80%, spec = 82%.
￿ ICO ≥ 2% better than 1, 5, 7 and 10%.
Duflo, 2001, ** [46] Mixed ICU, 104 pts Gram stain (mini-BAL) Mini-BAL (103) ￿ Gram stain: sens = 76%, spec = 100%, k = 0.73, 
concordance = 86%.
Mimoz, 2000, ** [50] Mixed ICU, 134 pts Gram stain (10 and 50 
fields)
PSB (103) or bPTC 
(103)
￿ Gram stain (10 fields) vs PSB: sens = 74%, spec = 94%.
￿ Gram stain (10 fields) vs PTC: sens = 81%, spec = 100%.
￿ Gram (50 fields): slight increase in spec, decrease in sens
￿ Morphology and PSB culture: sens = 54%, spec = 86%.
￿ Morpholgy and bPTC culture: sens = 69%, spec = 89%.
Allaouchiche, 1999, ** [51] Mixed ICU, 118 pts ICO (≥ 2%) & Gram stain 
(BAL)
PSB (103) ￿ ICO: sens = 86%, spec = 78%, PPV = 68%, NPV = 91%, 
k = 0.616, concordance 81.5%.
￿ Gram stain: sens = 90%, spec = 73%, PPV = 64%, NPV = 
91%; k = 0.58, concordance 79.4%.
￿ Correlation between morphology and culture: complete: 
51%, partial: 39.%, no correlation: 9.8%.
Allaouchiche, 1996, ** [52] Mixed ICU, 132 pts ICO PSB (103) + clinical 
evolution
￿ ICO (≥ 2%): sens = 84%, spec = 80%, PPV = 69%, NPV 
= 90%, ROC = 0.888.
Torres, 1996, *, ** [25] Mixed ICU, 25 pts ICO (≥ 5%), mini-BAL 
(104) & BAL (104)
Pathology ￿ ICO (≥ 5%) compared to mini-BAL: PPV = 75%, NPV = 
83%.
￿ ICO (≥ 5%) compared to BAL: PPV = 57%, NPV = 83%.
￿ Mini-BAL: sens = 22%, spec = 100%.
￿ BAL: sens = 45%, spec = 55%.
Sole-Violan, 1994, ** [68] Mixed ICU, 33 pts ICO (BAL) & BAL (104) & 
PSB (103)
Clinical ad hoc ￿ BAL: sens = 87%, spec = 100%.
￿ PSB: sens = 75%, spec = 100%.
￿ ICO (>4%): sens = 62%, spec = 100%.
Brasel, 2003, ** [66] Surgical ICU, 35 pts ICO 5% & ICO 7% TA (104) & TA (105) ￿ ICO 5% and TA (104): sens = 61%, spec = 89%, PPV = 
90%, NPV = 59%, ROC = 0.84.
￿ ICO 5% and TA (105): sens = 85%, spec = 82%, PPV = 
70%, NPV = 91%, ROC = 0.89.
￿ ICO 7% and TA (104): sens = 39%, spec = 97%, PPV = 
96%, NPV = 50%, ROC = 0.86.
￿ ICO 7% and TA (105): sens = 61%, spec = 91%, PPV = 
77%, NPV = 82%, ROC = 0.84.
Timsit, 2001, ** [65] Mixed ICU, 110 pts BAL-D (1% of infected 
cells)
BAL (104) & PSB 
(103)
￿ BAL-D: sens = 93%, spec = 91%, AUC = 0.953, PPV = 
90%, NPV = 98%.
Prekates, 1998, ** [47] Surgical and Trauma 
ICU, 75 pts,
Gram stain (BAL) BAL ￿ Gram stain: sens = 77%, spec = 87%, PPV = 71%, NPV = 
90%.
ICU = intensive care unit; BAL = bronchoalveolar lavage; CDC = center of disease control; sens = sensitivity; spec = specificity; PPV = positive predictive value; NPV 
= negative predictive value; ICO = intracellular organism; PSB = protected specimen brush; bPTC = blinded protected telescoping catheter; vs = versus; PTC = 
protected (plugged) telescoping catheter; TA = tracheal aspiration; BAL-D = direct examination of BAL; *retrospective; **consecutive; #convenient.Critical Care    Vol 12 No 2    Rea-Neto et al.
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critically ill mechanically ventilated patients, Determann et al.
[76] reported an increase in sTREM-1 levels in non-directed
BAL fluid obtained from patients who developed VAP (n = 9)
in contrast to those who did not. A cutoff value for BAL fluid
sTREM-1 levels of 200 pg/ml had a sensitivity of 75% and
specificity of 84% in diagnosing pneumonia.
The value of endotoxin measurements in BAL fluid was also
investigated, as approximately 70% of cases of VAP are
caused by Gram-negative bacteria. Flanagan et al. [77]
reported an increased concentration of endotoxin in broncho-
scopic BAL and non-directed BAL fluid of patients with VAP.
An endotoxin concentration of 6 EU/ml yielded the optimal
operating characteristics (sensitivity of 81% and specificity of
87%). In 40 samples of BAL fluid from patients with multiple
trauma requiring prolonged mechanical ventilation, Pugin et al.
[78] showed a relation between the concentration of endo-
toxin in lavage fluid and the quantity of Gram-negative bacteria.
An endotoxin level greater than or equal to 6 EU/ml distin-
guished patients with Gram-negative bacterial pneumonia
from colonized patients, and from those with pneumonia due
to Gram-positive cocci.
The studies evaluating the value of the previously mentioned
biomarkers are limited by the lack of a gold standard used to
diagnosis VAP. EF and sTREM-1 were compared to clinical
diagnosis ad hoc [75,76], PCT was compared to mini-BAL
[71], and CRP to Johanson criteria [73].
In summary: CRP, PCT, and sTREM are promising biomarkers
for diagnosing VAP, while EF and endotoxin concentrations
are of limited value. Further studies are needed to fully deter-
mine the diagnostic accuracy of these and other biomarkers.
Discussion
Evaluating the performance of various diagnostic tests in
patients with suspected VAP is challenging. The absence of a
good gold standard for comparison is the main limiting factor
in assessing these tests. Establishing a diagnosis of VAP,
based on pathology or histology plus culture of the lung tissue,
has a considerable degree of uncertainty, however, it is con-
sidered the best available gold standard [8]. Pathologic exam-
ination of lung tissue is not a perfect gold standard because
patients who die are not representative of all patients with
VAP. Moreover, many patients die after some days of antibiotic
administration, which may alter results of bacteriologic analy-
sis. In addition, pathology or tissue cultures may include non-
diseased lung tissue leading to false negative results, and
diagnostic criteria based on pathologic examination of lung tis-
sue are not well defined [27,79]. Fabregas et al. [79] found
that the histology and microbiology of post-mortem lung biop-
sies were poorly correlated, challenging the value of histologi-
cal examination of lung tissue in diagnosing VAP.
The etiology of VAP probably involves microaspiration of
secretions accumulating above the cuff of endotracheal tube
[80]. These foci of microinfection may remain localized caus-
ing local bronchiolitis without clinically relevant pneumonia or
proceed to develop into micro- or macro-bronchopneumonia.
The multifocal, heterogeneous nature of VAP is one of the rea-
sons why it is so difficult to establish a diagnosis of VAP.
Biopsy specimens can miss the area of active disease. Alter-
natively, positive results may represent an area of clinically
silent early bronchiolitis or resolving bronchial pneumonia.
Likewise, cultures can miss the area of active disease (yielding
false-negative results) or can detect clinically benign areas of
bacterial colonization (yielding false positive results). In addi-
tion, the many antibiotics given to critically ill patients may
decrease the diagnostic yield of bacterial cultures [24,79].
Table 7
Studies evaluating the value of biomarkers in diagnosing VAP
First author Sample Dx Tests Gold standard Results
Povoa, 2005, # [73] Mixed ICU, 112 pts CRP Johanson CRP (>9.6 mg/dl): sens = 87%, spec = 88%, AUC = 
0.92.
Gibot, 2004, ** [75] Mixed ICU, 148 pts sTREM-1 in mini-BAL Mini-BAL (103) Clinical (ad 
hoc)
Sens = 98%, spec = 90%.
Duflo, 2002, ** [71] Mixed ICU, 96 pts PCT serum & alveolar Mini-BAL (103) Serum PCT (≥3.9 ng/ml): sens = 41%, spec = 100%, 
AUC = 0787.
Alveolar PCT: not useful.
Oppert, 2002, ** [72] Mixed ICU, 28 pts PCT and PCR Clinical (ad hoc) Serum PCT (>1 ng/ml): sens = 100%, spec = 75%.
El-Ebiary, 1995, *, ** [69] Mixed ICU, 78 pts Elastin fibre Clinical (ad hoc) EF: sens = 32%, spec = 72%.
Determann, 2005, ** [76] Mixed ICU, 28 pts sTREM-1 Clinical & NBLF Sens = 75%, spec = 84%.
Pugin, 1992, ** [78] Trauma ICU, 40 pts BAL Endotoxin Clinical & BAL BAL endotoxin > 6 EU/ml suggests pneumonia due to 
Gram-negative bacteria.
Flanagan, 2001, ** [77] Mixed ICU, 64 pts BAL Endotoxin Clinical & BAL Sens = 81%, spec = 87%, PPV = 67%, NPV = 95%.
AUC: area under the curve; ICU = intensive care unit; CRP = C-reactive protein; sens = sensitivity; spec = specificity; sTREM-1 = soluble triggering receptor 
expressed on myeloid cells; BAL = bronchoalveolar lavage; PCT = procalcitonin; EF = elastin fiber; NBLF = non-directed bronchial lavage fluids; EU = endotoxin units; 
*retrospective; **consecutive; #convenient.Available online http://ccforum.com/content/12/2/R56
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Associated cardiorespiratory comorbidities are another
source of bias in diagnosing VAP. Autopsies of ventilated
patients with suspected pneumonia frequently reveal a sub-
stantial burden of alternative or coexisting pulmonary diseases
that can also cause fever, impaired gas exchange, increased
secretions, and radiographic opacities. These other conditions
include thromboembolic disease, hemorrhage, diffuse alveolar
damage, fibrosis, atelectasia, carcinoma, lymphoma, and oth-
ers [11,12,24,27,28]. The high prevalence of coexisting pul-
monary diseases in ventilated patients further complicates
attempts to clinically diagnose VAP.
The major limitation of the clinical approach to diagnosis is that
it consistently leads to more antibiotic therapy than when ther-
apy decisions are based on the findings of invasive lower res-
piratory tract samples. The clinical approach is overly sensitive,
and patients can be treated for pneumonia when another non-
infectious process is responsible for the clinical findings.
As none of the available diagnostic tests, performed alone, can
provide an accurate diagnosis of VAP, a diagnostic strategy
incorporating several criteria seems to be a good compromise.
On the basis of clinical data, patients with clinical suspicion of
VAP should be further evaluated by imaging procedures, bac-
teriological cultures, and biomarkers (Figure 1). The results of
complementary diagnostic procedures should be used to
refine the probability of diagnosing VAP and guide therapeutic
decisions. Quantitative cultures should be performed on
endotracheal aspirates or samples collected bronchoscopi-
cally, each technique having its own methodological limita-
tions. Delays in the initiation of adequate antibiotic therapy
increase mortality of VAP and thus therapy should not be post-
poned for the purpose of performing diagnostic studies in
patients who are clinically unstable. The presence of organ
dysfunction may necessitate the prompt initiation of antibiotic
therapy. Garrard and A'Court [81] recommended regular,
repeated surveillance with a simple, inexpensive, and well tol-
erated lavage technique in addition to daily clinical scoring to
identify patients who may have VAP. A recent meta-analysis
[82] of four randomized studies with a total of 628 patients
showed that invasive strategies for the diagnosis of VAP did
not alter mortality. In a recent multicenter trial, Heyland et al.
[83] randomized 740 patients who were receiving mechanical
ventilation and who had suspected VAP after 4 days in the ICU
to undergo either BAL with quantitative culture of the BAL fluid
or endotracheal aspiration with non-quantitative culture of the
aspirate. Empirical antibiotic therapy was initiated in all
patients until culture results were available, at which point a
protocol of targeted therapy was used for discontinuing or
reducing the dose or number of antibiotics, or for resuming
antibiotic therapy to treat a pre-enrollment condition if the cul-
ture was negative. There was no significant difference in out-
comes or the use of antibiotics. The most likely explanation for
this lack of effect on outcome is that prompt adequate initial
antimicrobial coverage is the crucial issue affecting survival.
Inappropriate or inadequate treatment refers to the use of anti-
Figure 1
Summary of the management strategies for a patient with suspected hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or  healthcare-associated pneumonia (HCAP) Summary of the management strategies for a patient with suspected hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or 
healthcare-associated pneumonia (HCAP). The decision about antibiotic discontinuation may differ depending on the type of sample collected 
(PSB, BAL, or endotracheal aspirate), and whether the results are reported in quantitative or semiquantitative terms. From [1] (with permission).Critical Care    Vol 12 No 2    Rea-Neto et al.
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biotics with either limited or no in vitro activity against the
microorganism causing the infection. Since invasive sampling
for suspected VAP does not directly affect the initial antibiotic
prescription, it is not surprising that it does not alter mortality.
Because of the nature of the technology, the culture results
from bronchoscopy become available only after the crucial
period when the clinician can intervene to maximal effect [82].
Conclusion
Clinical criteria, used in combination, may be helpful in diag-
nosing VAP; however, the considerable inter-observer variabil-
ity and the moderate performance should be taken into
account. Bacteriologic data do not increase the accuracy of
diagnosis as compared to clinical diagnosis. Quantitative cul-
tures obtained by different methods, including BAL, pBAL,
PSB or TBA seem to be rather equivalent in diagnosing VAP.
Blood cultures are relatively insensitive to diagnose pneumo-
nia. The rapid availability of cytological data, including inflam-
matory cells and Gram stains, may be useful in initial
therapeutic decisions in patients with suspected VAP. CRP,
PCT, and sTREM are promising biomarkers in diagnosing
VAP. An integrated approach should be followed in diagnos-
ing and treating patients with VAP, including early antibiotic
therapy and subsequent rectification according to clinical
response and results of bacteriologic cultures.
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